Josh Enomoto

Josh Enomoto

InvestorPlace Contributor

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

7 Monster Growth Stocks With Double-Digit Upside

By Josh Enomoto, InvestorPlace Contributor

With several growth stocks encountering a steep discount from the coronavirus panic, many early speculators have benefitted tremendously. However, those getting in late to the game still have a chance at upside.

Why Catalyst Pharmaceuticals Stock Is Feeling the ‘Bern’

By Josh Enomoto, InvestorPlace Contributor

Typically, a major clinical victory would boost names like Catalyst Pharmaceuticals stock. Unfortunately, some political rumblings and an unexpected competitor got in the way of CPRX.

The Low-Hanging Fruit for Covid-19 Vaccines Is Gone for iBio

By Josh Enomoto, InvestorPlace Contributor

With the viable candidate pool for novel coronavirus vaccines shrinking, this angle is probably closed to IBIO stock. However, speculators still have a shot with the therapeutic approach.

Why the FDA’s Inquiry of Inovio Is More Critical Than You Think

By Josh Enomoto, InvestorPlace Contributor

INO stock tumbled due to the FDA asking questions about the underlying DNA vaccine. Here’s why you should be concerned.

Big Data Doesn’t Exempt Palantir Technologies From Big Problems

By Josh Enomoto, InvestorPlace Contributor

There’s no doubt that big data has changed our world and PLTR stock is levered to this still rapidly growing sector. However, headwinds associated with the pandemic may impede Palantir Technologies’ progress.

Load More